1) CMQ has no choice but to source out manufacturing as there is...

1) CMQ has no choice but to source out manufacturing as there is no possible funding for any expansion. Then there is the technical (impossibility?) to scale up as they cant even get MP1 to 20tpa let alone 50tpa.
2) Quote: Adopt and build a comprehensive approach and focused marketing approach to new markets.

What a load of bull – new markets where there is no approval is going to bring in REVENUE? What happened to the present market Mr Williams had identified in earlier presentations, in particular the South African Dreamland where a container load of products had been DELIVERED to an unconditional sale not financed by CMQ & under normal commercial terms? So what’s the real problem in the existing markets? No new contracts, no revenue and no future?

Quote: “In the past we have perhaps tried to market our product too broadly. By changing the emphasis of our marketing to target specific diseases, our customer will more readily adopt the product”. CMQ had been very specific in its approach; that is to replace the antibiotic currently used in animal feed. Has CMQ the antibiotics strategy fail? There goes the dream sales?And welcome to the Great Coccidiosis sideshow to take the eye of the main issue! And the human health market is much easier than the veterinary market? Is this a joke?

In the past the excuse was the lack of production capacity. It appears the sales receipts is less than 2 ton (if we believe they can achieve $1M per T!!!) which the APVMA approved pilot plant can comfortably produce out of the car park. Now it is no longer possible to use production capacity excuse, marketing strategy it seems is the reason for lack of sales? What's next? CO2 emmission perhaps?

3). WAITING FOR Stark’s Strategic Review. Any pharmaceutical (CMQ's dream strategic partners) could have it for a song through Stark!

Cheers.